Compare · RCKT vs RKT
RCKT vs RKT
Side-by-side comparison of Rocket Pharmaceuticals Inc. (RCKT) and Rocket Companies Inc. (RKT): market cap, price performance, sector, and recent activity on the wire.
Summary
- RCKT operates in Health Care, while RKT operates in Finance - the two are in different parts of the market.
- RKT is the larger of the two at $42.44B, about 119.6x RCKT ($354.9M).
- Over the past year, RCKT is up 29.1% and RKT is up 5.3% - RCKT leads by 23.7 points.
- RKT has been more active in the news (23 items in the past 4 weeks vs 2 for RCKT).
- Both have 25 recent analyst ratings on file.
- Company
- Rocket Pharmaceuticals Inc.
- Rocket Companies Inc.
- Price
- $3.24+0.31%
- $14.97+1.29%
- Market cap
- $354.9M
- $42.44B
- 1M return
- +8.18%
- +4.83%
- 1Y return
- +29.08%
- +5.35%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Finance: Consumer Services
- Exchange
- NASDAQ
- NYSE
- IPO
- 2015
- 2020
- News (4w)
- 2
- 23
- Recent ratings
- 25
- 25
Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating pediatric diseases. It has four clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia; and infantile malignant osteopetrosis, a genetic disorder characterized by increased bone density and bone mass secondary to impaired bone resorption. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. It has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; CIEMAT and UCL Business PLC; The Regents of the University of California; and REGENXBIO Inc. The company also has a research and collaboration agreement with Lund University; and strategic collaboration agreement with Stanford University School of Medicine. Rocket Pharmaceuticals, Inc. is headquartered in Cranbury, New Jersey.
Rocket Companies Inc.
Rocket Companies, Inc. engages in the tech-driven real estate, mortgage, and eCommerce businesses in the United States and Canada. It operates in two segments, Direct to Consumer and Partner Network. The company's solutions include Rocket Mortgage, a mortgage lender; Amrock that provides title insurance, property valuation, and settlement services; Rocket Homes, a home search platform and real estate agent referral network, which offers technology-enabled services to support the home buying and selling experience; Rocket Auto, an automotive retail marketplace that provides centralized and virtual car sales support to national car rental and online car purchasing platforms; and Rocket Loans, an online-based personal loans business. Its solutions also include Core Digital Media, a digital social and display advertiser in the mortgage, insurance, and education sectors; Nexsys, a fintech company, which offers a suite of essential tech solutions for mortgage origination and closing processes through digitization and automation; Lendesk, a technology services company that provides a point of sale system for mortgage professionals and a loan origination system for private lenders; and Edison Financial, a digital mortgage startup. In addition, the company originates, closes, sells, and services agency-conforming loans. Rocket Companies, Inc. was founded in in 1985 and is headquartered in Detroit, Michigan. Rocket Companies, Inc. is a subsidiary of Rock Holdings, Inc.
Latest RCKT
- Rocket Pharmaceuticals Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Regulation FD Disclosure, Financial Statements and Exhibits
- Rocket Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $180 Million
- Amendment: SEC Form SC TO-I/A filed by Rocket Pharmaceuticals Inc.
- SEC Form 4 filed by Officer Militello John
- Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences
- CEO Shah Gaurav exercised 76,490 shares at a strike of $1.69 and sold $171,841 worth of shares (55,684 units at $3.09), increasing direct ownership by 2% to 1,061,724 units (SEC Form 4)
- General Counsel Wilson Martin sold $1,995 worth of shares (662 units at $3.01), decreasing direct ownership by 0.10% to 677,977 units (SEC Form 4) to satisfy withholding tax
- CEO Shah Gaurav sold $7,261 worth of shares (2,409 units at $3.01), decreasing direct ownership by 0.23% to 1,040,918 units (SEC Form 4) (withholding tax)
- Officer Militello John sold $1,157 worth of shares (384 units at $3.01), decreasing direct ownership by 0.43% to 89,780 units (SEC Form 4) (for tax liability)
- Rocket Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
Latest RKT
- Americans Across Party Lines Back Policies to Improve Housing Affordability: Redfin Survey
- Fewer Homeowners Are Listing as Spring Market Ends With a Whimper, Not a Bang
- Redfin Reports Flood-Prone Parts of America Are Losing Residents at Nearly Twice Last Year’s Rate
- NYC Suburbs and the Bay Area Are This Spring’s Most Competitive Housing Markets
- U.S. Home-Price Growth Accelerated in May, Fueled by April’s Brief Mortgage-Rate Reprieve
- Redfin Reports 46% of Home Sellers Gave Concessions to Buyers in May, the Highest Share on Record For That Month
- Housing Payments Hit 1-Year High, Sending Buyers to the Sidelines
- Former Red-Hot Seller's Markets, Like Atlanta, Now Lead the Nation in Canceled Home Sales
- Rocket Companies Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement
- Rocket Companies downgraded by BTIG Research